Why do Business With Israel?

Israel's unmatched pool of highly skilled workers, world-renowned research capabilities, and free trade agreements with all major economic powers make it the ideal place to do business.

In no other time in recent history have political, economical and regulatory factors converged with such strength to affect major change in healthcare systems worldwide. The financial crisis has exacerbated realities faced by governments and healthcare providers, and accelerated changing trends.

To address this issue, the ILSI Biomed 2010 Conference will focus on:

• The role of innovation, its source – industry or academia? Who will pay for it? – venture capital or large medical and BioPharma companies?
• Regulatory changes and their impact on innovation
• Does personalized medicine mean smaller target markets?
• Who is better suited to commercialize future “niche” products? Large players or innovative fully integrated companies. How would it impact business models?  

We will take a closer look at cardiology, vaccines, oncology, cell therapy, personalized medicine, metabolic diseases and the aesthetic medicine markets. All these discussions will serve as background to the presentations given by 60 more than 60 Israeli medical device and BioPharma companies.

Please join Israel’s vibrant life science community at the 9th ILSI Biomed annual conference, where science, technology and industry leadership come together. Connect with old and new friends, explore business relationships and learn about the future of healthcare through a variety of panels on hot industry topics and trends, world-class speakers, and high-quality networking opportunities. Join top-notch industry executives, Israel’s most innovative medical device and BioPharma entrepreneurs, major pharmaceutical companies, life science research leaders, policy makers and internationally prominent industry investors.

ILSI Biomed 2010 follows the success of previous annual conferences: last year’s event drew 6,000 industry players, engineers and scientists, with 800 participants from 35 countries and in excess of 2,500 one-on-one meetings. We will continue our tradition of keynote speeches and plenary sessions given by industry leaders and leading academicians, worldwide.  And we will continue with our successful tradition of offering one-on-one partnering sessions and an extensive exhibition area.